Ashfield UK makes two new business development appointments for its growing team
pharmafile | October 16, 2015 | Appointment | Medical Communications | Ashfield UK
Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located at the company’s global headquarters in Ashby de la Zouch, Leicestershire.
David Tweedale joins Ashfield following 11 years at Merz Pharma in numerous roles, most recently as a sales and marketing manager.
During this time he was responsible for successful sales and marketing strategy development and implementation for the therapeutic portfolio and identifying opportunities to expand and grow the business unit across Northern Europe. He also successfully launched and managed a direct competitor to Botox. Tweedale joined the business on September 1.
Ian Robinson spent 18 years working for Bristol-Myers Squibb in a number of roles including sales representative, account manager and regional business director. Following the transfer of the Bristol-Myers Squibb diabetes business to AstraZeneca in February 2014, Robinson took up the role of diabetes national sales lead, with responsibility for sales strategy and operational excellence of the field team.
He has been involved in a number of successful launches in both cardiovascular and diabetes products, most recently launching the first in a new class of drugs for type 2 Diabetes. Ian joined the business on September 28.
On announcing the appointments, Colin Watson, managing director for Ashfield UK, comments: “We are thrilled to welcome David and Ian to the business development team. They both bring a great deal of knowledge and experience to our organisation and have joined the business at very exciting time.”
(Image caption: David Tweedale (l) and Ian Robinson (r)
